354 related articles for article (PubMed ID: 30177605)
1. Use of Polyamidoamine Dendrimers in Brain Diseases.
Florendo M; Figacz A; Srinageshwar B; Sharma A; Swanson D; Dunbar GL; Rossignol J
Molecules; 2018 Sep; 23(9):. PubMed ID: 30177605
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of polyamidoamine dendrimers as potential carriers for quercetin, a versatile flavonoid.
Madaan K; Lather V; Pandita D
Drug Deliv; 2016; 23(1):254-62. PubMed ID: 24845475
[TBL] [Abstract][Full Text] [Related]
3. Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers.
Yiyun C; Tongwen X
Eur J Med Chem; 2005 Nov; 40(11):1188-92. PubMed ID: 16153746
[TBL] [Abstract][Full Text] [Related]
4. In vitro gene delivery using polyamidoamine dendrimers with a trimesyl core.
Zhang XQ; Wang XL; Huang SW; Zhuo RX; Liu ZL; Mao HQ; Leong KW
Biomacromolecules; 2005; 6(1):341-50. PubMed ID: 15638538
[TBL] [Abstract][Full Text] [Related]
5. Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery.
Gu Z; Wang M; Fang Q; Zheng H; Wu F; Lin D; Xu Y; Jin Y
Drug Dev Ind Pharm; 2015 May; 41(5):812-8. PubMed ID: 24745851
[TBL] [Abstract][Full Text] [Related]
6. PAMAM dendrimers: destined for success or doomed to fail? Plain and modified PAMAM dendrimers in the context of biomedical applications.
Labieniec-Watala M; Watala C
J Pharm Sci; 2015 Jan; 104(1):2-14. PubMed ID: 25363074
[TBL] [Abstract][Full Text] [Related]
7. Highly lipophilic pluronics-conjugated polyamidoamine dendrimer nanocarriers as potential delivery system for hydrophobic drugs.
Nguyen TTC; Nguyen CK; Nguyen TH; Tran NQ
Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 2):992-999. PubMed ID: 27772731
[TBL] [Abstract][Full Text] [Related]
8. Polyamidoamine Dendrimers for Enhanced Solubility of Small Molecules and Other Desirable Properties for Site Specific Delivery: Insights from Experimental and Computational Studies.
Shadrack DM; Swai HS; Munissi JJE; Mubofu EB; Nyandoro SS
Molecules; 2018 Jun; 23(6):. PubMed ID: 29895742
[TBL] [Abstract][Full Text] [Related]
9. Half generations magnetic PAMAM dendrimers as an effective system for targeted gemcitabine delivery.
Parsian M; Mutlu P; Yalcin S; Tezcaner A; Gunduz U
Int J Pharm; 2016 Dec; 515(1-2):104-113. PubMed ID: 27725272
[TBL] [Abstract][Full Text] [Related]
10. Low systemic toxicity nanocarriers fabricated from heparin-mPEG and PAMAM dendrimers for controlled drug release.
Thanh VM; Nguyen TH; Tran TV; Ngoc UP; Ho MN; Nguyen TT; Chau YNT; Le VT; Tran NQ; Nguyen CK; Nguyen DH
Mater Sci Eng C Mater Biol Appl; 2018 Jan; 82():291-298. PubMed ID: 29025661
[TBL] [Abstract][Full Text] [Related]
11. Dendrimer-Based Drug Delivery Systems for Brain Targeting.
Zhu Y; Liu C; Pang Z
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31783573
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug.
Ma M; Cheng Y; Xu Z; Xu P; Qu H; Fang Y; Xu T; Wen L
Eur J Med Chem; 2007 Jan; 42(1):93-8. PubMed ID: 17095123
[TBL] [Abstract][Full Text] [Related]
13. Conjugation of polyamidoamine dendrimers on biodegradable microparticles for nonviral gene delivery.
Zhang XQ; Intra J; Salem AK
Bioconjug Chem; 2007; 18(6):2068-76. PubMed ID: 17848077
[TBL] [Abstract][Full Text] [Related]
14. Transport of surface engineered polyamidoamine (PAMAM) dendrimers across IPEC-J2 cell monolayers.
Pisal DS; Yellepeddi VK; Kumar A; Palakurthi S
Drug Deliv; 2008 Nov; 15(8):515-22. PubMed ID: 18720134
[TBL] [Abstract][Full Text] [Related]
15. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo.
Malik N; Wiwattanapatapee R; Klopsch R; Lorenz K; Frey H; Weener JW; Meijer EW; Paulus W; Duncan R
J Control Release; 2000 Mar; 65(1-2):133-48. PubMed ID: 10699277
[TBL] [Abstract][Full Text] [Related]
16. Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats.
Lin Y; Fujimori T; Kawaguchi N; Tsujimoto Y; Nishimi M; Dong Z; Katsumi H; Sakane T; Yamamoto A
J Control Release; 2011 Jan; 149(1):21-8. PubMed ID: 20184931
[TBL] [Abstract][Full Text] [Related]
17. Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo.
Liu C; Liu X; Rocchi P; Qu F; Iovanna JL; Peng L
Bioconjug Chem; 2014 Mar; 25(3):521-32. PubMed ID: 24494983
[TBL] [Abstract][Full Text] [Related]
18. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study.
Cheng Y; Qu H; Ma M; Xu Z; Xu P; Fang Y; Xu T
Eur J Med Chem; 2007 Jul; 42(7):1032-8. PubMed ID: 17336426
[TBL] [Abstract][Full Text] [Related]
19. PAMAM dendrimers for the delivery of the antibacterial Triclosan.
Gardiner J; Freeman S; Leach M; Green A; Alcock J; D'Emanuele A
J Enzyme Inhib Med Chem; 2008 Oct; 23(5):623-8. PubMed ID: 18821252
[TBL] [Abstract][Full Text] [Related]
20. Amino acid-functionalized dendrimers with heterobifunctional chemoselective peripheral groups for drug delivery applications.
Navath RS; Menjoge AR; Wang B; Romero R; Kannan S; Kannan RM
Biomacromolecules; 2010 Jun; 11(6):1544-63. PubMed ID: 20415504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
